| Medical and Health Sciences | Lifetime | 426 | US 229 | 99.98 |
| Medical and Health Sciences | 2021-2025 | 102 | US 40 | 99.98 |
| Pulmonary and Respiratory Medicine | Lifetime | 4 | US 3 | 99.99 |
| Oncology | Lifetime | 46 | US 26 | 99.92 |
| Cancer Research | Lifetime | 449 | US 237 | 97.23 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 6 | US 2 | 99.97 |
| Oncology | 2021-2025 | 19 | US 7 | 99.89 |
| Molecular Biology | 2021-2025 | 288 | US 77 | 98.71 |
| Cancer Research | 2021-2025 | 237 | US 82 | 87.15 |
| Lung Cancer Treatments and Mutations | Lifetime | 1 | US 1 | 99.99 |
| Lung Cancer Research Studies | Lifetime | 1 | US 1 | 99.96 |
| Colorectal Cancer Treatments and Studies | Lifetime | 5 | US 2 | 99.96 |
| Cancer therapeutics and mechanisms | Lifetime | 7 | US 4 | 99.86 |
| HER2/EGFR in Cancer Research | Lifetime | 15 | US 7 | 99.91 |
| Cancer Genomics and Diagnostics | Lifetime | 45 | US 29 | 99.86 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 23 | US 14 | 99.74 |
| Lung Cancer Diagnosis and Treatment | Lifetime | 100 | US 52 | 99.65 |
| Peptidase Inhibition and Analysis | Lifetime | 228 | US 106 | 98.99 |
| Pleural and Pulmonary Diseases | Lifetime | 94 | US 50 | 98.91 |
| Occupational and environmental lung diseases | Lifetime | 83 | US 38 | 98.85 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 513 | US 263 | 98.85 |
| Gastric Cancer Management and Outcomes | Lifetime | 581 | US 184 | 98.77 |
| Cancer Mechanisms and Therapy | Lifetime | 183 | US 92 | 97.98 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | Lifetime | 570 | US 169 | 97.84 |
| Cancer Research and Treatments | Lifetime | 705 | US 371 | 96.68 |
| Advanced Breast Cancer Therapies | Lifetime | 448 | US 210 | 96.45 |
| Protein Degradation and Inhibitors | Lifetime | 648 | US 316 | 95.62 |
| Melanoma and MAPK Pathways | Lifetime | 400 | US 212 | 96.02 |
| Protein Tyrosine Phosphatases | Lifetime | 426 | US 170 | 91.96 |
| Quinazolinone synthesis and applications | Lifetime | 698 | US 120 | 90.82 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 5 | US 1 | 99.97 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 1 | US 1 | 99.11 |
| Lung Cancer Research Studies | 2021-2025 | 7 | US 2 | 99.91 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 8 | US 2 | 99.84 |
| HER2/EGFR in Cancer Research | 2021-2025 | 17 | US 7 | 99.70 |
| Lung Cancer Diagnosis and Treatment | 2021-2025 | 42 | US 14 | 99.30 |
| Cancer Genomics and Diagnostics | 2021-2025 | 158 | US 80 | 98.82 |
| Cancer therapeutics and mechanisms | 2021-2025 | 34 | US 16 | 97.18 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 161 | US 63 | 96.72 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 624 | US 234 | 97.63 |
| Cancer Treatment and Pharmacology | 2021-2025 | 175 | US 54 | 96.64 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 599 | US 111 | 95.52 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 526 | US 233 | 94.84 |
| Advanced Breast Cancer Therapies | 2021-2025 | 274 | US 101 | 95.16 |
| Peptidase Inhibition and Analysis | 2021-2025 | 432 | US 115 | 92.19 |
| Ubiquitin and proteasome pathways | 2021-2025 | 621 | US 154 | 85.66 |
| Protein Tyrosine Phosphatases | 2021-2025 | 72 | US 24 | 85.34 |
| Melanoma and MAPK Pathways | 2021-2025 | 295 | US 98 | 85.99 |
| Protein Degradation and Inhibitors | 2021-2025 | 878 | US 368 | 85.43 |
| Protein Kinase Regulation and GTPase Signaling | 2021-2025 | 120 | US 65 | 80.29 |
| Cancer Mechanisms and Therapy | 2021-2025 | 907 | US 123 | 72.48 |
| Biochemical and Molecular Research | 2021-2025 | 569 | US 119 | 70.10 |
| Quinazolinone synthesis and applications | 2021-2025 | 629 | US 31 | 61.62 |
